[Pituitary adenoma treated with a somatostatin analog].
We studied for over 7 months the use of SMS 201-995, in 1 woman with pituitary adenoma. Eight years after surgical and irradiation therapy, adenoma relapsed with hyperthyroidism (T4 L = 71pmol/l, TSH = 5.3 mU/l, subunit: 309 micrograms/l) and was complicated by meningitis. It was invasive and removed only partly. SMS therapy, 100 micrograms SC q 8 h, allowed partial reduction of clinical hyperthyroidism and decreased TSH and alpha subunit of 47%. Increased dosage and changing route of administration did not increase efficacy. A modest decrease of adenoma was probably caused by several reasons. In summary in an adenoma unusual by the extremely high value of alpha subunit in contrast with modest value of TSH, SMS therapy allowed partial control only.
Houdent
C
C
Clinique Médicale B, CHU de Rouen, Hôpital de Boisguillaume.
Armangau
M F
MF
Kuhn
J M
JM
Delangre
T
T
Tadie
M
M
Clavier
E
E
Basuyau
J P
JP
Sassolas
G
G
Wolf
L M
LM
D000236:Adenoma / Q000150:complications / Q000188:drug therapy* / Q000473:pathology; D005260:Female; D006801:Humans; D006980:Hyperthyroidism / Q000150:complications; D015282:Octreotide / Q000627:therapeutic use*; D010911:Pituitary Neoplasms / Q000150:complications / Q000188:drug therapy* / Q000473:pathology; D013963:Thyroid Hormones / Q000097:blood; D013972:Thyrotropin / Q000097:blood
D013963:Thyroid Hormones; D013972:Thyrotropin; D015282:Octreotide
Adénome thyréotrope traité par un analogue de la somatostatine.